Opus Genetics, Inc.

IRDNASDAQKern
US$4.11
+1.99 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: George MagrathEmployees: 28Market cap: 339 MIPO: 19/01/2015Web: opusgtx.com

Opus Genetics, Inc. (IRD) is a US-based healthcare and biotechnology company specializing in the clinical development of biopharmaceuticals with a focus on ophthalmology. Its portfolio includes innovative therapeutic approaches for the treatment of refractive and retinal diseases. A key component is Phentolamine…

Brief assessment by a strategy agent, last updated on 04/08/2026. Not investment advice.

PRICE HISTORY

25/08/25+257.4 %25/08/26

1D

+2 %

1W

+11.4 %

1M

+33.4 %

6M

+12.9 %

YTD

+104.5 %

1Y

+257.4 %

2Y

–

5Y

–

10Y

–

EARNINGS

Next earnings date

11/11/2026 (in 77 days)

Volatility around earnings

~-25% stronger price swings than usual

SCORES

ValuationTrendQualityDividendGrowthInsiderEarningsRevisionsSentimentShort Pressure
Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Clear downtrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are selling significantly more shares than they buy.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Not enough data yet for an assessment.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Persistently high short volume ratio, partly with a Reg SHO threshold listing.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

  • 4 credits free on registration
  • Access to virtual portfolios and watchlist
  • No credit card, no payment details needed
  • No subscription, no minimum term
  • Our own servers in Germany, no US cloud
Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT IRD

ANALYST ASSESSMENT

PRICE TARGET LOW

US$8.00

CONSENSUS

US$9.00

MEDIAN

US$9.00

PRICE TARGET HIGH

US$10.00

0

STRONG BUY

8

BUY

0

HOLD

0

SELL

0

STRONG SELL

8

TOTAL · Buy

DATEANALYST FIRMRATINGACTION
07/08/2026RBC CapitalOutperformmaintain
06/07/2026Chardan CapitalBuymaintain
06/07/2026BTIGBuymaintain
18/06/2026Chardan CapitalBuymaintain
17/06/2026HC Wainwright & Co.Buymaintain
16/06/2026BTIGBuymaintain
15/06/2026CitizensMarket Outperformmaintain
13/05/2026CitizensMarket Outperformmaintain

METRICS

P/E

-3.24

P/B

-30.22

EV/EBITDA

-2.72

RETURN ON EQUITY

62.4 %

NET MARGIN

-1,072.6 %

DEBT/EQUITY

-2.69

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

42.4 %

FLOAT SHARES

34,978,921

AVG. DAILY VOLUME (30D)

869,072

INSIDER TRANSACTIONS (SEC)

DATEINSIDERROLETRANSACTIONSHARESPRICEPLAN TYPE
27/07/2026Gagnon Robert E.OfficerSale7,7832.95Spontaneous
27/07/2026Magrath GeorgeOfficerSale9,4752.95Spontaneous
27/07/2026SCHACHLE JOSEPH KOfficerSale4,6442.94Spontaneous
27/07/2026YERXA BENJAMIN ROfficerSale7,4292.97Spontaneous
20/05/2026Foundation Fighting Blindness Retinal Degeneration FundDirectorSale1,700,0004.35Spontaneous
Page 1 / 3

ATTENTION

Price since yesterday: +2.0%

Search (Google Trends)

28/0711/0826/08

Basis: Google Search Trends, as of 2026-08-25. Attention is risk information, not a buy or sell signal.

STOCK SPLITS

DATERATIO
06/11/20201:4
12/04/20191:12
05/05/20171:10
23/05/20051:100

Not investment advice. Past performance is not an indicator of future results.